Arrowhead Pharmaceuticals, Inc.
ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial toā¦ read more
Healthcare
Biotechnology
31 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$41.26
Price+0.29%
$0.12
1Y
Price
Market Cap
$5.705b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-596.2%
EBITDA Margin-631.1%
Net Profit Margin-565.7%
Free Cash Flow MarginRevenue
$596.565m
+16699.9%
1y CAGR+5533.5%
3y CAGR+4169.1%
5y CAGREarnings
-$148.417m
+75.2%
1y CAGR-44.5%
3y CAGR-39.6%
5y CAGREPS
-$1.30
+74.0%
1y CAGR-33.8%
3y CAGR-31.0%
5y CAGRBook Value
$517.299m
$1.381b
Assets$666.276m
Liabilities$112.700m
DebtDebt to Assets
8.2%
-1.6x
Debt to EBITDAFree Cash Flow
-$17.621m
+97.1%
1y CAGR-20.2%
3y CAGR-72.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company